Your browser doesn't support javascript.
loading
An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis.
Werfel, T; Irvine, A D; Bangert, C; Seneschal, J; Grond, S; Cardillo, T; Brinker, D; Zhong, J; Riedl, E; Wollenberg, A.
Afiliación
  • Werfel T; Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.
  • Irvine AD; Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.
  • Bangert C; Department of Clinical Medicine, Trinity College, Dublin, Ireland.
  • Seneschal J; Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Grond S; Department of Dermatology and Pediatric Dermatology and National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Bordeaux, France.
  • Cardillo T; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Brinker D; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Zhong J; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Riedl E; IQVIA, Durham, North Carolina, USA.
  • Wollenberg A; Eli Lilly and Company, Indianapolis, Indiana, USA.
J Eur Acad Dermatol Venereol ; 36(9): 1486-1496, 2022 Sep.
Article en En | MEDLINE | ID: mdl-35490395
ABSTRACT

BACKGROUND:

Atopic dermatitis (AD) is associated with an increased risk for viral infections including those caused by herpes simplex virus and varicella zoster virus.

OBJECTIVES:

This study examined treatment-emergent (TE) herpes simplex infection including eczema herpeticum (EH), and herpes zoster (HZ), in adult patients with AD receiving ≥1 dose of baricitinib (BARI), an oral selective inhibitor of Janus kinase 1/2.

METHODS:

We evaluated data from six double-blinded, randomized, placebo-controlled (PC) trials and two long-term extension studies, within three analysis sets PC, 2-4-mg BARI extended and All-BARI-AD. Frequency, incidence rate (IR)/100 person-years (PYs) and clinical characteristics of TE-herpes simplex, EH and HZ were reported.

RESULTS:

In the All-BARI-AD dataset (n = 2531; 2247 PYs), herpes simplex was reported in 8.9% of patients (n = 224; IR = 10.3). Most herpes simplex events were rated as mild or moderate (93.3%), rarely led to permanent discontinuation (2.2%) and presented mostly as oral/perioral herpes simplex (51.3%). TE-EH occurred at a low frequency (All-BARI-AD 1.7% n = 43; IR = 2.0) and were reported in 0.5%, 0.2% and 1.4% of patients receiving placebo, 2-mg or 4-mg BARI respectively. In the All-BARI-AD dataset, most events were investigator-rated as mild/moderate (79.1%), affected ≤2% of the body surface area (74.2%) and occurred as single events (88.4%). Serious TE-EH (n = 11) occurred exclusively in patients with poor disease control (vIGA-AD™ score ≥3) at infection onset. TE-HZ was reported in 2.1% of BARI patients (n = 53; IR = 2.3), without a dose relationship during the PC period (IR = 2.7 and IR = 0.0) or the extended dataset (IR = 3.7 and IR = 1.7) for 2- or 4-mg BARI respectively.

CONCLUSIONS:

TE-herpes simplex was common, while occurrence of EH was uncommon. Most events of EH were localized with involvement of a small BSA and were linked to poor disease control. Events of HZ were rare in the PC dataset and without a dose dependent increase in frequency.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Azetidinas / Dermatitis Atópica / Herpes Simple Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Azetidinas / Dermatitis Atópica / Herpes Simple Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2022 Tipo del documento: Article País de afiliación: Alemania